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SHORT COMMUNICATION
Frequency of raised ax-fetoprotein level among Chinese patients with
hepatoceilular carcinoma related to hepatitis B and C
J.-F. Tsai', W.Y. Chang', J.E. Jeng2, M.S. Ho3, Z.Y. Lin' & J.H. Tsai'
'Department ofInternal Medicine and 2Clinical Laboratory, Kaohsiung Medical College; 3Institute ofBiomedical Sciences,
Academia Sinica, Taiwan, Republic ofChina.
Summary Antibody to hepatitis C virus (anti-HCV) was found to be an independent risk factor for
hepatocellular carcinoma and raised serum a-fetoprotein (AFP) level. In addition, the frequency of raised AFP
in patients with anti-HCV was higher than in those without (91.5% vs 65.2%, P = 0.0001).
Serum a-fetoprotein (AFP) may be elevated in patients with
chronic liver disease and hepatocellular carcinoma (HCC)
(Chen & Sung, 1979; Lee et al., 1991; Sherlock & Dooley,
1993). In Taiwan, HCC is closely associated with hepatitis B
virus and hepatitis C virus (HCV) infection (Chen & Sung,
1979; Jeng & Tsai, 1991; Sheu et al., 1992; Tsai et al.,
1994a,b). There is no relationship between serum hepatitis B
surface antigen (HBsAg) and AFP level (Chen & Sung, 1979;
Lee et al., 1991). However, the relationship between HCV
infection and serum AFP level has never been clearly
defined.
This study aimed to determine the frequency of raised
AFP level among Chinese patients with HCC related to
hepatitis B and C.
Materials and methods
Study population
The study population comprised 177 consecutive newly diag-
nosed HCC patients admitted to Kaohsiung Medical College
Hospital from July 1990 to July 1992. All patients were
diagnosed by pathology or aspiration cytology. There were
151 men and 26 women, with ages ranging from 32 to 81
(mean 59) years. During the same period, 177 healthy indi-
viduals with normal serum transaminase levels were enrolled
from a community around the hospital. Community controls
were individually matched with cases for age (± 5 years) and
sex. There was no statistically significant difference in the
mean age and sex between patients and controls. This study
was approved by the Investigation and Ethics Committee of
the hospital.
Serological examination
HBsAg and AFP were tested with Ausria II and a-feto
RIABEAD (Abbott Laboratories, North Chicago, IL, USA)
respectively. Conventional liver functional tests were per-
formed using a sequential multiple autoanalyser.
Anti-HCV was detected with Abbott HCV EIA 2nd
Generation (Abbott Laboratories). Positive samples were
retested with the same assay and another second-generation
synthetic peptide-based immunoassay (UBI HCV EIA,
United Biochemical, Lake Success, NY, USA). Only samples
positive in all three tests were considered to be anti-HCV
positive.
Statistical analysis
An unpaired Student t-test and chi-square test with Yates'
correction were used when appropriate. The correlation
between continuous variables was analysed by linear regres-
sion. The odds ratio with 95% confidence interval was cal-
culated in order to estimate causal relations between risk
factors and exposure. The incremental odds ratio was cal-
culated to assess the difference between risk estimated by
HBV and HCV. Stepwise logistic regression was performed
for multivariate analysis. An a-value of 0.05 was used as the
indicator of statistical significance.
Results
The prevalences of anti-HCV (33.3%) and -HBsAg (68.4%)
in patients with HCC were higher than those in healthy
controls (2.2% and 19.2%, respectively, P = 0.0001). Table I
indicates that both HBV and HCV infection were indepen-
dent risk factors of HCC.
Serum AFP in patients with HCC (33,559 + 11,917 ngnml-')
was higher than that in controls (3.2 ± 0.6 ng ml-'-;
P = 0.0001). Raised AFP was defined as an AFP level greater
than 20 ng ml-' (Chen & Sung, 1979; Sherlock & Dooley,
1993). Serum AFP in all controls was lower than 20 ng ml'- .
Raised AFP was detected in 131 (74.0%) patients. There
were 95 (53.6%) patients with an AFP level higher than
400 ng ml-'. Serum AFP correlated positively with aspartate
aminotransferase (r = 0.201, P = 0.007), alanine aminotrans-
ferase (r = 0.178, P= 0.017), alkaline phosphatase (r = 0.152,
P = 0.042) and y-glutamyltranspeptidase (r = 0.305, P =
0.0001). The results of conventional liver function tests in
patients with raised AFP were worse than in patients with
normal AFP (Table II). The prevalence of raised AFP in
patients with anti-HCV (91.5%) was higher than in patients
without (65.2%, P =0.0001). Serum AFP was not signifi-
cantly correlated with HBsAg status, sex, age or presence or
absence of cirrhosis in patients with HCC (Table II).
Both univariate and multivariate analysis demonstrated
that only anti-HCV is a significant risk factor for raised AFP
(Table III). In addition, the risk for raised AFP in patients
with anti-HCV alone was significantly higher than in patients
with HBsAg alone (incremental odds ratio 16.9). There was
no significant correlation between tumour size and AFP level
(r = 0.195; n = 127).
Discussion
This study demonstrates that HCV infection is a risk factor
for HCC and raised AFP level among Chinese patients with
HCC (Tables I and III). The frequency of raised AFP was
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Table I Risk for HCC related to hepatitis B and C virus infection evaluated by
univariate and multivariate analysis
HCC Control Odds ratio Adjusted odds ratioa
Variables (n = 177) (n = 177) (95% CI) (95% CI)
Anti-HCV + 59 4 21.6 (7.2-48.2) 8.0 (4.5-14.0)
HBsAg+ 121 34 9.0 (5.4-15.3) 4.5 (3.3-6.0)
aDerived from stepwise logistic regression analysis. CI, confidence interval; HBsAg,
hepatitis B surface antigen; anti-HCV, antibody to hepatitis C virus.
Table II Clinical characteristics of patients with hepatocellular carcinoma by the
status of serum a-fetoprotein level
AFP <20ngml-' AFP >20ngml-'
(n = 46) (n = 131) Probability
Sex (M:F) 37:9 114:17 Nsa
Cirrhosis (%) 89.1 83.9 NS
HBsAg + (%) 78.2 64.8 NS
Anti-HCV + (%) 10.8 41.2 0.0001
Age (year) 58.2ill.Ol.Ob 57.1 10.6 NS
Albumin (gdl-') 3.5 ± 0.6 3.3 ± 0.6 0.014
Globulin (gdl-') 2.9 0.9 3.3 ±0.7 0.023
Bilirubin (mg dl-')
Direct 0.3 ±0.3 1.3 ±2.4 0.006
Indirect 1.1 0.8 2.3 2.9 0.008
AST (IUl') 95.2 103.7 206.5 195.8 0.011
ALT (IU1-1) 59.2 45.7 106.1 ± 176.4 NS
ALP (IU l-) 126.9 78.9 195.0 157.8 0.006
GGT (IU 1-) 97.3 ± 88.4 204.5 ± 195.8 0.001
aNot significant. bData was expressed as mean ± s.d. AFP, a-fetoprotein; AST,
aspartic aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phos-
phatase; GGT, 1-glutamyltranspeptidase.
Table III Risk for raised serum x-fetoprotein level modified by hepatitis B
and C virus infection in patients with hepatocellular carcinoma
AFP (ngml-')
HBsAg Anti-HCV >20 <20 Odds ratio'
status status (n = 131) (n = 46) (95% CI)
Negative Negative 11 9 1.0b
Positive Negative 66 32 1.6 (0.5-4.9)C
Negative Positive 35 1 28.6 (3.0-178.8)bc
Positive Positive 19 4 3.8 (0.8-19.9)
aStepwise logistic regression analysis indicated that only anti-HCV was an
independent risk factor (adjusted odds ratio 3.3; 95% CI 1.9-5.7;
P = 0.0001). bp = 0.0001. cIncremental odds ratio = 16.9 (95% CI 2.3-89.7);
P = 0.0001. AFP, a-fetoprotein; CI, confidence interval; HBsAg, hepatitis B
surface antigen; anti-HCV, antibody to hepatitis C virus.
significantly related to anti-HCV positivity, even when higher
cut-off values (50 and lOOngml-') were used (data not
shown). Why are AFP levels more likely to be abnormal in
anti-HCV-positive patients with HCC? We speculate that
these patients have more advanced disease (Tsai et al., 1993,
1994c; Yano et al., 1993), that they are older than anti-HCV-
negative patients (60.3 ± 8.8 vs 56.1 ± 11.2 years; P = 0.015)
and that HBsAg carriers are being regularly followed up for
chronic sequelae.
In this study, HBsAg and anti-HCV were detected by
radioimmunoassay and second-generation assay respectively.
Some of the patients negative for either marker may well be
positive on detection of HBV DNA or HCV RNA by poly-
merase chain reaction (Sheu et al., 1992). On the other hand,
it is possible that HCV RNA may be absent in some of our
anti-HCV-positive patients (Sheu et al., 1992).
In conclusion, HCV-infected individuals should be
regarded as a high-risk group in mass population surveillance
programmes for HCC. A thorough examination for HCC
should be done if AFP becomes elevated during follow-
up.
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